The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC Human umbilical vein endothelial cells.
The ED50 for this effect is typically 9-20 ng/ml in the presence of 5 ng/ml rhVEGF165.
< 1.000 Eu/µg
>95% by SDS-PAGE .
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
pH: 7.40 Constituents: 95% PBS, 5% Trehalose
This product is an active protein and may elicit a biological response in vivo, handle with caution.
It is recommended to reconstitute the lyophilized protein in sterile deionized water (check coa for lot no specific volume) to a final concentration of 400 ug/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% HSA or BSA) is strongly recommended for further dilution and long term storage.
Fetal liver kinase 1
FLK1, mouse, homolog of
Kinase insert domain receptor
Kinase insert domain receptor (a type III receptor tyrosine kinase)
Protein tyrosine kinase receptor FLK1
Protein-tyrosine kinase receptor flk-1
Tyrosine kinase growth factor receptor
Vascular endothelial growth factor receptor 2
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. Contains 7 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain.
Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.